The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted to ...

Esketamine nasal spray (Spravato) monotherapy was helpful in improving symptoms of treatment-resistant depression, a ...

Australian researchers have discovered that a bedtime nasal spray has the potential to reduce ... diabetes, anxiety and ...

The spray – which was approved by the FDA in March – has a wholesale acquisition cost of $295 per 28 mg device and costs around $32,400 for a year’s treatment, says ICER.

in a nasal spray and half were given a placebo. The study found those using esketamine had a much greater improvement in depression symptoms at all points over the first four weeks of treatment.

When Dr. Husseini Manji was developing the first-in-class depression medication Spravato at Johnson & Johnson he encountered plenty of naysayers.

nasal spray for depression disorders, AV-101 oral NMDR glycine site antagonist for depression and neurological disorders, PH15 acute treatment for improvement of cognition, PH80 acute management ...

We primarily treat Treatment-Resistant Depression, Major Depressive Disorder, and Generalized Anxiety Disorder. Using effective, FDA-approved TMS and Spravato nasal spray treatments, we help ...